SCHEMBL4377766

SCHEMBL4377766

Cc1ccccc1S(=O)(=O)N1CCC(=NOC(c2ccc(F)cc2)c2ccc(F)cc2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR3C1 P04150 1/20 0.40
▸ KMT2A Q03164 5/20 0.40
▸ MEN1 O00255 4/20 0.40
▸ DCTPP1 Q9H773 2/20 0.39
▸ ALDH1A1 P00352 4/20 0.39
▸ MAPK1 P28482 2/20 0.39
▸ HTT P42858 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ TSHR P16473 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ CYP1A2 P05177 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ CYP2C9 P11712 1/20 0.37
▸ PKM P14618 1/20 0.36
▸ SMN1; SMN2 Q16637 3/20 0.36
▸ EPHX2 P34913 1/20 0.36
▸ FAAH O00519 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ MAPT P10636 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4377015 0.88 PKM (0.46) KMT2AMEN1ALDH1A1LMNATSHR
SCHEMBL4376961 0.84 PKM (0.50) NR3C1ALDH1A1TSHRKDM4ETDP1
SCHEMBL4380941 0.84 CHRM1 (0.39) KMT2AMEN1ALDH1A1CYP2C9PKM
SCHEMBL4381279 0.82 PKM (0.49) KMT2AMEN1ALDH1A1LMNAKDM4E
SCHEMBL4385272 0.82 PKM (0.54) KMT2AALDH1A1LMNATSHRKDM4E
SCHEMBL4378960 0.82 PKM (0.43) ALDH1A1TSHRKDM4EPKMMAPT
SCHEMBL4380325 0.81 L3MBTL1 (0.35) KMT2AMEN1ALDH1A1LMNATSHR
SCHEMBL13589018 0.80 MEN1 (0.38) KMT2AMEN1ALDH1A1LMNACYP1A2
SCHEMBL4379527 0.79 PKM (0.37) KMT2AMEN1ALDH1A1TSHRCYP1A2
SCHEMBL4384838 0.79 FABP1 (0.57) ALDH1A1MAPK1TSHRL3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 — — US disclosed
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 — — US disclosed
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF PURDUE PHARMA L.P. 2009-12-03 — — US disclosed
WO-2008008398-A2 OXIME COMPOUNDS AND THE USE THEREOF SHIONOGI & CO., LTD. (JP) 2008-01-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298878-A1 OXIME COMPOUNDS AND THE USE THEREOF KCNN4, CACNA1A, KCNN3 NR3C1 1874/4885KMT2A 2079/4885MEN1 3694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback